Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist sold by Novo Nordisk. It is FDA-approved for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and heart disease. Wegovy is the same molecule with a higher dose labeled for chronic weight management. Rybelsus is the oral tablet form of semaglutide for type 2 diabetes.
The wholesale list price for an Ozempic pen is approximately $998 per month in 2026. What you actually pay depends on your insurance, your indication (diabetes vs. weight loss), and whether you qualify for the manufacturer's savings card or patient assistance program. This guide breaks down the real 2026 prices by coverage type and the rules that matter most. Patients prescribed Ozempic for weight loss instead of diabetes should compare Wegovy, which is the same molecule at a higher dose and covered by different rules. Mounjaro and Zepbound are tirzepatide alternatives worth reviewing.
Demand for Ozempic and Wegovy surged through 2024 and 2025, putting pressure on insurers and Medicare. The Inflation Reduction Act selected semaglutide (Ozempic, Rybelsus, Wegovy) for the second round of Medicare price negotiation. Negotiated prices for these drugs are scheduled to take effect in 2027. For now, Medicare patients with diabetes who cannot afford Ozempic should check whether Medicare covers GLP-1 weight loss drugs or whether Medicaid covers GLP-1s by state.
What Ozempic Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same ozempic can cost many times more at a hospital than at your local pharmacy:
2026 Ozempic Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $950 - $1,350/month | List price without insurance for a 28-day pen |
| Medicare Part D (2026) | $0 - $200/month, capped at $2,100/year | Diabetes only. Wegovy (weight loss) is not covered. |
| Commercial insurance | $25 - $300/month after PA | Prior authorization is standard. Step therapy is common. |
| Novo Nordisk savings card | $25/month (24-month cap, commercial only) | Ineligible if you have Medicare, Medicaid, or no insurance |
| Medicaid | $1 - $4/prescription, with PA | Covered for type 2 diabetes; weight-loss use varies by state |
Retail prices reflect 2026 GoodRx and pharmacy survey data. Part D ranges depend on your plan's formulary tier and where you are in your benefit year.
Source: CMS Part D 2026 benefit design, Novo Nordisk savings programs, GoodRx
Why Hospitals Charge So Much
Ozempic is rarely administered in a hospital setting because it is a self-injected, once-weekly outpatient prescription drug. When it does appear on a hospital bill, usually because the patient brought their pen from home or the hospital dispensed a partial supply, the charge can run several times the retail rate. Hospitals routinely add facility fees, pharmacy handling fees, and nursing administration charges on top of the drug's acquisition cost.
If you see Ozempic on an inpatient itemized bill at $1,500 or more for a partial pen, ask for the line-item cost and the NDC number. The 2026 wholesale acquisition cost for a single pen is around $750 to $850. Charges far above that are often facility markups that can be negotiated or appealed. Most commercial insurance and Medicare will only pay the outpatient pharmacy rate, leaving the hospital markup to the patient unless disputed.
Patient Assistance Programs
Novo Nordisk, the manufacturer of Ozempic, Wegovy, and Rybelsus, runs several programs that can substantially lower the cost. Eligibility depends on your insurance status and income.
Patient assistance programs for Ozempic| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Ozempic Savings Card | $25/month for up to 24 months for commercial-insured patients with type 2 diabetes | ozempic.com/savings |
| Novo Nordisk Patient Assistance Program (NovoCare) | Free Ozempic for uninsured patients at or below 400% FPL | novocare.com/pap |
| Wegovy Savings Offer | $0 - $225/month for commercial-insured patients (varies by plan coverage) | wegovy.com/savings |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies | needymeds.org |
Manufacturer savings cards are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by law (anti-kickback statute). If you have government insurance, apply for the Novo Nordisk PAP instead.
Source: Novo Nordisk patient program pages, NeedyMeds.org
Medicare Part D
Ozempic is a Medicare Part D drug. For 2026, your total annual out-of-pocket cost for all Part D drugs combined is capped at $2,100. That cap is from the Inflation Reduction Act and replaced the old catastrophic phase coinsurance. Once you hit $2,100 in out-of-pocket spending in a calendar year, you pay $0 for the rest of the year on covered drugs, including Ozempic.
Medicare covers Ozempic for type 2 diabetes only. By statute, Medicare Part D does not cover drugs used for weight loss. That means Wegovy (semaglutide for obesity) is not covered under Medicare even though it is the same molecule. In 2024, CMS clarified that Medicare may cover Wegovy when prescribed to reduce cardiovascular risk in patients with established heart disease and obesity, but not for weight loss alone. Always confirm coverage with your plan before filling.
You can also use the Medicare Prescription Payment Plan starting in 2025, which lets you spread your Part D out-of-pocket costs evenly across the year instead of paying a large amount in a single month. Ask your Part D plan to enroll you in this payment plan if Ozempic causes a high upfront bill.
Common Ozempic Billing Errors
If you got a bill for Ozempic above $300 with commercial insurance, or above $200/month on Medicare Part D, check for these issues before paying:
- Prior authorization not submitted or denied without appeal: most plans require PA for Ozempic. If your prescriber's office did not submit one, you may be paying cash unnecessarily.
- Wegovy billed under Ozempic codes, or vice versa. They have different NDCs and different coverage rules. Confirm the dispensed product matches the prescription.
- Multi-pen pack billed as multiple separate fills, doubling or tripling your copay. Each pen contains four weekly doses; one pen per month should equal one copay.
- Charged the deductible rate after you already hit the $2,100 Part D out-of-pocket cap for the year.
- Manufacturer savings card not applied at the pharmacy counter even though you are eligible. Ask the pharmacist to rerun the claim with the savings card BIN/PCN.
- Inpatient hospital charge for an Ozempic dose marked up to several thousand dollars when retail is around $1,000.
Frequently Asked Questions
How much does Ozempic cost without insurance in 2026?
The cash retail price for Ozempic in 2026 is approximately $950 to $1,350 per 28-day pen, depending on the pharmacy and pen strength. The wholesale list price is around $998 per month. GoodRx and similar discount programs sometimes shave 5 to 10 percent off the retail price. If you are uninsured and earn at or below 400 percent of the federal poverty level, the Novo Nordisk Patient Assistance Program can supply Ozempic free of charge.
Does Medicare cover Ozempic?
Yes, Medicare Part D covers Ozempic for type 2 diabetes. Your specific copay depends on your plan's formulary tier, but your total out-of-pocket spending on all Part D drugs combined is capped at $2,100 in 2026 thanks to the Inflation Reduction Act. Medicare does not cover Ozempic when prescribed solely for weight loss, and Medicare does not cover Wegovy except in narrow cardiovascular-risk-reduction cases.
Why doesn't Medicare cover Wegovy?
Federal law (the Medicare Modernization Act of 2003) prohibits Medicare Part D from covering drugs used for weight loss. Wegovy is FDA-approved for chronic weight management, so it falls under that exclusion. In March 2024, CMS announced that Medicare can cover Wegovy when prescribed to reduce cardiovascular events in adults with established heart disease and obesity, but not for weight loss alone. Wegovy and Ozempic are the same molecule (semaglutide) but have different FDA labels and different Medicare coverage.
What is the difference between Ozempic, Wegovy, and Rybelsus?
All three are semaglutide made by Novo Nordisk. Ozempic is a once-weekly injection approved for type 2 diabetes at doses up to 2 mg. Wegovy is a once-weekly injection approved for chronic weight management at a higher 2.4 mg dose. Rybelsus is a daily oral tablet approved for type 2 diabetes. Coverage and cost differ significantly: Ozempic and Rybelsus are widely covered for diabetes, but Wegovy is excluded from most Medicare plans and many commercial plans.
Can I use the Ozempic savings card with Medicare?
No. Federal anti-kickback law bars manufacturer copay savings cards from being used by anyone on Medicare, Medicaid, TRICARE, or VA benefits. The Ozempic savings card is for commercially-insured patients only and caps your copay at $25 per month for up to 24 months. If you are on Medicare, your option is the Novo Nordisk Patient Assistance Program, which provides free Ozempic for incomes up to 400 percent of FPL.
What is the 2026 Medicare Part D out-of-pocket cap?
In 2026, the Medicare Part D annual out-of-pocket cap is $2,100. That is the maximum you will pay across all your Part D prescription drugs combined in a calendar year. Once you reach $2,100 in out-of-pocket spending, you pay $0 for covered drugs for the rest of the year. The cap was $2,000 in 2025 and is indexed to inflation under the Inflation Reduction Act.
Will my commercial insurance cover Ozempic for weight loss?
Most commercial insurance plans cover Ozempic only for the FDA-approved indication (type 2 diabetes) and require prior authorization. Some plans cover Wegovy for weight loss if you meet BMI and comorbidity criteria, but coverage is shrinking as employers drop GLP-1 weight-loss coverage to control costs. Check your plan's formulary directly, and ask your prescriber's office to file the PA paperwork with the correct ICD-10 code.
Why does my hospital bill show Ozempic at over $1,500?
Inpatient hospital pharmacies bill drugs at facility rates that include the acquisition cost plus markups for pharmacy handling, nursing administration, and overhead. A single Ozempic pen with a wholesale cost near $750 can be billed at $1,500 to $4,000 in an inpatient setting. Request an itemized bill, look up the National Drug Code (NDC), and compare to the wholesale acquisition cost. Charges far above $1,000 per pen are common dispute targets.
